March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Merck (MRK) announced the opening of a new, $1B, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site. This expansion of our Durham plant is a ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...

DURHAM, N.C. (WTVD) -- Drugmaker Merck announced Tuesday the opening of a new facility in North Durham. The $1 billion plant will manufacture the HPV vaccines Gardasil and Gardasil 9, while the ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new ...

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to sidestep more than 200 cases claiming the company concealed safety risks.

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and ...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According ...

Keysight Technologies: "I think this company is doing incredibly well...Good stock." Merck: "Merck is too cheap...I think you buy the stock of Merck." Click here to download Jim Cramer's Guide to ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...